A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of GDC-0199 (ABT-199) In Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Chop) In Patients With B-Cell Non-Hodgkins Lymphoma (NHL) and DLBCL
This is a multicentre, open-label, dose-finding study of GDC-0199 administered orally in
combination with MabThera/Rituxan (R) or obinutuzumab (G) and standard doses of
cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in patients with
Non-Hodgkins Lymphoma (NHL). Patients will be randomized to one of two treatment arms of
GDC-0199 in combination with R-CHOP and G-CHOP. The study will consist of two stages, a
dose-finding stage and an expansion stage. The maximum tolerated dose (MTD) of GDC-0199 in
combination with R-CHOP and G-CHOP will be determined during the dose-finding stage.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society